These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy. Babacan NA; Eroglu Z Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651 [TBL] [Abstract][Full Text] [Related]
6. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in managing metastatic melanoma: which treatment when? Amaral T; Meraz-Torres F; Garbe C Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339 [TBL] [Abstract][Full Text] [Related]
8. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096 [TBL] [Abstract][Full Text] [Related]
9. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? Kelley MC Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Luke JJ Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886 [TBL] [Abstract][Full Text] [Related]
12. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. Hu-Lieskovan S; Robert L; Homet Moreno B; Ribas A J Clin Oncol; 2014 Jul; 32(21):2248-54. PubMed ID: 24958825 [TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE Front Immunol; 2021; 12():661737. PubMed ID: 34025662 [TBL] [Abstract][Full Text] [Related]
14. Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Tomei S; Wang E; Delogu LG; Marincola FM; Bedognetti D Expert Opin Biol Ther; 2014 May; 14(5):663-86. PubMed ID: 24625306 [TBL] [Abstract][Full Text] [Related]
15. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876 [TBL] [Abstract][Full Text] [Related]
16. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943 [TBL] [Abstract][Full Text] [Related]
17. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203 [TBL] [Abstract][Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075 [TBL] [Abstract][Full Text] [Related]
20. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]